DHR Stock Recent News
DHR LATEST HEADLINES
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Danaher (DHR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
DHR stands to benefit from strength in the clinical diagnostics business, Abcam buyout and shareholder-friendly policies. Softness in the Instrument unit remains a concern.
Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Automated and Closed Cell Therapy Market 2024-2029" report has been added to ResearchAndMarkets.com's offering.
WASHINGTON , Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m.
BREA, Calif. and TEL AVIV, Israel , Sept.
WASHINGTON , Sept. 4, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event.
Investors with an interest in Diversified Operations stocks have likely encountered both Hitachi Ltd. (HTHIY) and Danaher (DHR).
Danaher's high valuation and flat 2024 EPS growth might raise eyebrows, but its track record, strategic acquisitions, and long-term growth potential make it a solid buy for those who can. Despite trading at a premium, Danaher's strong history, efficient operations, and potential for double-digit EPS growth in 2025 make it one of the few stocks I'm buying at a lofty price. Danaher's blend of strategic acquisitions and operational efficiency makes it a long-term winner. I'm adding to my position despite the high P/E, expecting strong returns as growth picks up.
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?